{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T17:38:09Z","timestamp":1771954689839,"version":"3.50.1"},"reference-count":166,"publisher":"Oxford University Press (OUP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,10,1]]},"DOI":"10.1093\/ehjcvp\/pvw044","type":"journal-article","created":{"date-parts":[[2017,2,16]],"date-time":"2017-02-16T06:48:13Z","timestamp":1487227693000},"page":"221-234","source":"Crossref","is-referenced-by-count":41,"title":["Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors"],"prefix":"10.1093","volume":"3","author":[{"given":"Max-Paul","family":"Winter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik L.","family":"Grove","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaele","family":"De Caterina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana A.","family":"Gorog","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingo","family":"Ahrens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias","family":"Geisler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul A.","family":"Gurbel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Udaya","family":"Tantry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eliano P.","family":"Navarese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jolanta M.","family":"Siller-Matula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,2,15]]},"reference":[{"key":"key\n\t\t\t\t20171011230541_pvw044-B1","first-page":"267","article-title":"2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the","volume":"37","year":"2016","journal-title":"European Society of Cardiology (ESC). Eur Heart J"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B2","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1093\/eurheartj\/eht296","article-title":"2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology","volume":"34","year":"2013","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B3","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1093\/eurheartj\/ehs215","article-title":"ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation","volume":"33","author":"Task Force on the management of STseamiotESoC","year":"2012","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B4","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1161\/01.CIR.0000130846.46168.03","article-title":"Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction","volume":"109","year":"2004","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B5","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1161\/01.CIR.0000072771.11429.83","article-title":"Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity","volume":"107","year":"2003","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B6","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ccd.10497","article-title":"Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation","volume":"59","year":"2003","journal-title":"Catheter Cardiovasc Interv"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B7","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1016\/j.jacc.2013.07.101","article-title":"Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding","volume":"62","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B8","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.jcin.2013.06.011","article-title":"Epa. Response variability to P2Y12 receptor inhibitors: expectations and reality","volume":"6","year":"2013","journal-title":"JACC Cardiovasc Interv"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B9","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3109\/09537104.2013.877581","article-title":"Comparison of the antiplatelet effect of two clopidogrel bisulfate formulations: Plavix and generic-Egitromb","volume":"26","year":"2015","journal-title":"Platelets"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B10","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.jacc.2006.10.050","article-title":"Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?","volume":"49","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B11","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.jacc.2008.11.030","article-title":"Platelet Reactivity After Clopidogrel Treatment Assessed With Point-of-Care Analysis and Early Drug-Eluting Stent Thrombosis","volume":"53","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B12","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/eurheartj\/ehp402","article-title":"Early but not late stent thrombosis is influenced by residual platelet aggregation in patients undergoing coronary interventions","volume":"31","year":"2010","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B13","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1538-7836.2009.03699.x","article-title":"Multiple Electrode Aggregometry predicts stent thrombosis better than the VASP assay","volume":"8","year":"2010","journal-title":"J Thromb Haemost"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B14","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1016\/j.jacc.2007.01.094","article-title":"Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis","volume":"49","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B15","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1161\/CIRCULATIONAHA.109.883454","article-title":"High residual platelet reactivity after clopidogrel loading and long-term clinical outcome after drug-eluting stenting for unprotected left main coronary disease","volume":"120","year":"2009","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B16","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.jacc.2008.05.032","article-title":"Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents","volume":"52","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B17","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.amjcard.2009.06.007","article-title":"Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients","volume":"104","year":"2009","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B18","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1016\/j.jacc.2005.07.056","article-title":"Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results","volume":"46","year":"2005","journal-title":"of the CREST Study. J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B19","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1160\/TH06-07-0362","article-title":"High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes","volume":"97","year":"2007","journal-title":"Thromb Haemost"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B20","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1160\/TH13-02-0145","article-title":"Genetic variation of platelet function and pharmacology:An update of current knowledge","volume":"110","year":"2013","journal-title":"Thromb Haemost"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B21","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1080\/09537100802351065","article-title":"Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: a potential antiplatelet therapeutic target","volume":"19","year":"2008","journal-title":"Platelets"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B22","first-page":"27","article-title":"Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention:","volume":"47","year":"2006","journal-title":"the role of dual drug resistance. J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B23","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.jacc.2008.10.045","article-title":"Bivalirudin and clopidogrel with and without eptifibatide for elective stenting: effects on platelet function, thrombelastographic indexes, and their relation to periprocedural infarction results of the CLEAR PLATELETS-2 (Clopidogrel with Eptifibatide to Arrest the Reactivity of Platelets) study","volume":"53","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B24","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.thromres.2015.12.021","article-title":"Association between high on-treatment platelet reactivity and occurrence of cerebral ischemic events in patients undergoing percutaneous coronary intervention","volume":"138","year":"2016","journal-title":"Thromb Res"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B25","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1001\/jama.2010.181","article-title":"Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation","volume":"303","year":"2010","journal-title":"Jama"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B26","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.jacc.2006.06.065","article-title":"Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement","volume":"48","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B27","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1161\/01.CIR.0000157138.02645.11","article-title":"Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study","volume":"111","year":"2005","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B28","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1538-7836.2012.04639.x","article-title":"Phenotyping versus Genotyping for Prediction of Clopidogrel Efficacy and Safety: the PEGASUS-PCI study","volume":"10","year":"2012","journal-title":"J Thromb Haemost"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B29","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jacc.2010.03.048","article-title":"Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: initial evidence","volume":"56","year":"2010","journal-title":"of a therapeutic window. J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B30","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/j.1538-7836.2009.03709.x","article-title":"Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement","volume":"8","year":"2010","journal-title":"J Thromb Haemost"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B31","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.ahj.2010.02.025","article-title":"Dual low response to acetylsalicylic acid and clopidogrel is associated with myonecrosis and stent thrombosis after coronary stent implantation","volume":"159","year":"2010","journal-title":"Am Heart J"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B32","first-page":"16","article-title":"Assessment of platelet response with Multiplate impedance aggregometry in patients with coronary stents on Clopidogrel and aspirin treatment","volume":"17","year":"2011","journal-title":"Kardiologia"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B33","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1160\/TH11-02-0077","article-title":"Multiple electrode aggregometry and vasodilator stimulated phosphoprotein-phosphorylation assay in clinical routine for prediction of postprocedural major adverse cardiovascular events","volume":"106","year":"2011","journal-title":"Thromb Haemost"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B34","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jacc.2011.04.017","article-title":"High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes","volume":"58","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B35","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.ahj.2010.05.034","article-title":"Adenosine diphosphate-induced platelet-fibrin clot strength: a new thrombelastographic indicator of long-term poststenting ischemic events","volume":"160","year":"2010","journal-title":"Am Heart J"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B36","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1016\/j.jacc.2010.12.047","article-title":"Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome","volume":"57","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B37","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.thromres.2010.01.013","article-title":"Relationship between platelet reactivity inhibition and non-CABG related major bleeding in patients undergoing percutaneous coronary intervention","volume":"126","year":"2010","journal-title":"Thromb Res"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B38","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.jcin.2013.04.009","article-title":"Clinical implications of very low on-treatment platelet reactivity in patients treated with thienopyridine: the POBA study (predictor of bleedings with antiplatelet drugs)","volume":"6","year":"2013","journal-title":"JACC Cardiovasc Interv"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B39","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.amjcard.2011.08.034","article-title":"Residual platelet reactivity, bleedings, and adherence to treatment in patients having coronary stent implantation treated with prasugrel","volume":"109","year":"2012","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B40","doi-asserted-by":"crossref","first-page":"5344","DOI":"10.2174\/138161212803251925","article-title":"Interindividual variability in the efficacy of oral antiplatelet drugs: definitions, mechanisms and clinical importance","volume":"18","year":"2012","journal-title":"Curr Pharm Des"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B41","doi-asserted-by":"crossref","first-page":"531","DOI":"10.2337\/dc08-2064","article-title":"Antiplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions","volume":"32","year":"2009","journal-title":"Diabetes Care"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B42","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1538-7836.2007.02812.x","article-title":"The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score","volume":"6","year":"2008","journal-title":"J Thromb Haemost"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B43","first-page":"1765","article-title":"Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis","volume":"306","year":"2011","journal-title":"Jama"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B44","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1741-7015-9-3","article-title":"Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance\u2013the BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy","volume":"9","year":"2011","journal-title":"BMC Med"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B45","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1681\/ASN.2010020220","article-title":"Low responsiveness to clopidogrel increases risk among CKD patients undergoing coronary intervention","volume":"22","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B46","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.atherosclerosis.2010.07.023","article-title":"Impact of inflammatory markers on platelet inhibition and cardiovascular outcome including stent thrombosis in patients with symptomatic coronary artery disease","volume":"213","year":"2010","journal-title":"Atherosclerosis"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B47","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.amjcard.2013.09.011","article-title":"Impact of obesity and the metabolic syndrome on response to clopidogrel or prasugrel and bleeding risk in patients treated after coronary stenting","volume":"113","year":"2014","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B48","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1161\/hc4801.100029","article-title":"Platelet glycoprotein IIb\/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes","volume":"104","year":"2001","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B49","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jacc.2006.03.038","article-title":"Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment","volume":"48","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B50","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1161\/CIRCULATIONAHA.109.913376","article-title":"Diabetes and antiplatelet therapy in acute coronary syndrome","volume":"123","year":"2011","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B51","doi-asserted-by":"crossref","first-page":"H1480","DOI":"10.1152\/ajpheart.2001.280.4.H1480","article-title":"Platelet hyperactivity and abnormal Ca(2+) homeostasis in diabetes mellitus","volume":"280","year":"2001","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B52","doi-asserted-by":"crossref","first-page":"462","DOI":"10.2337\/db06-0390","article-title":"Alterations of adenine nucleotide metabolism and function of blood platelets in patients with diabetes","volume":"56","year":"2007","journal-title":"Diabetes"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B53","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1093\/eurheartj\/ehp159","article-title":"Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial","volume":"30","year":"2009","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B54","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1111\/j.1538-7836.2012.04875.x","article-title":"Relationship between post-treatment platelet reactivity and ischemic and bleeding events at one year follow-up in patients receiving prasugrel","volume":"10","year":"2012","journal-title":"J Thromb Haemost"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B55","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.ahj.2011.07.026","article-title":"Prasugrel overcomes high on-clopidogrel platelet reactivity in chronic coronary artery disease patients more effectively than high dose (150\u2009mg) clopidogrel","volume":"162","year":"2011","journal-title":"Am Heart J"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B56","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1111\/j.1538-7836.2011.04531.x","article-title":"Antiplatelet Effects of Prasugrel vs Double Clopidogrel in Patients on Hemodialysis and High On-Treatment Platelet Reactivity","volume":"9","year":"2011","journal-title":"J Thromb Haemost"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B57","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1161\/CIRCINTERVENTIONS.112.972323","article-title":"Randomized Assessment of Ticagrelor Versus Prasugrel Antiplatelet Effects in Patients with ST-Segment-Elevation Myocardial Infarction","volume":"5","year":"2012","journal-title":"Circ Cardiovasc Interv"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B58","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/j.jacc.2013.01.024","article-title":"Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study","volume":"61","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B59","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3109\/09537104.2013.863857","article-title":"Predictors of antiplatelet response to prasugrel during maintenance treatment","volume":"26","year":"2015","journal-title":"Platelets"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B60","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1111\/j.1538-7836.2011.04531.x","article-title":"Antiplatelet effects of prasugrel vs. double clopidogrel in patients on hemodialysis and with high on-treatment platelet reactivity","volume":"9","year":"2011","journal-title":"J Thromb Haemost"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B61","doi-asserted-by":"crossref","first-page":"506","DOI":"10.3109\/09537104.2013.845874","article-title":"Prasugrel or double-dose clopidogrel to overcome clopidogrel low-response\u2013the TAILOR (Thrombocytes And IndividuaLization of ORal antiplatelet therapy in percutaneous coronary intervention) randomized trial","volume":"25","year":"2014","journal-title":"Platelets"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B62","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jacc.2012.03.050","article-title":"Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study","volume":"60","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B63","article-title":"Inter-patient variability of platelet reactivity in patients treated with prasugrel and ticagrelor","year":"2015","journal-title":"Platelets"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B64","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.vph.2016.01.003","article-title":"Distribution of clinical events across platelet aggregation values in all-comers treated with prasugrel and ticagrelor","volume":"79","year":"2016","journal-title":"Vascul Pharmacol"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B65","first-page":"6):660","article-title":"Aging of platelet nitric oxide signaling: pathogenesis, clinical implications, and therapeutics","volume":"40","year":"2014","journal-title":"Semin Thromb Hemost"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B66","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/S0735-1097(01)01238-4","article-title":"Stable angina and acute coronary syndromes are associated with nitric oxide resistance in platelets","volume":"37","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B67","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1161\/CIRCULATIONAHA.111.047498","article-title":"Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial","volume":"124","year":"2011","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B68","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/MJT.0b013e31825e7aab","article-title":"Exploring PLATO-USA paradox and CURRENT-OASIS 7 trials reveals the benefit of higher aspirin dose","volume":"22","year":"2015","journal-title":"Am J Ther"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B69","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s10557-016-6671-4","article-title":"New Developments in Platelet Cyclic Nucleotide Signalling: Therapeutic Implications","volume":"30","year":"2016","journal-title":"Cardiovasc Drugs Ther"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B70","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.jacc.2008.07.055","article-title":"Calcium-channel blockers reduce the antiplatelet effect of clopidogrel","volume":"52","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B71","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1160\/TH09-08-0516","article-title":"The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response","volume":"103","year":"2010","journal-title":"Thromb Haemost"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B72","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1016\/j.jacc.2010.02.031","article-title":"Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement","volume":"55","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B73","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1111\/j.1538-7836.2011.04483.x","article-title":"Combined influence of proton-pump inhibitors, calcium-channel blockers and CYP2C19*2 on on-treatment platelet reactivity and on the occurrence of atherothrombotic events after percutaneous coronary intervention","volume":"9","year":"2011","journal-title":"J Thromb Haemost"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B74","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jacc.2007.06.064","article-title":"Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study","volume":"51","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B75","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.jacc.2009.05.050","article-title":"Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study","volume":"54","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B76","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1111\/j.1538-7836.2010.04049.x","article-title":"Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis","volume":"8","year":"2010","journal-title":"J Thromb Haemost"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B77","doi-asserted-by":"crossref","first-page":"148.e1","DOI":"10.1016\/j.ahj.2008.09.017","article-title":"Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel","volume":"157","year":"2009","journal-title":"Am Heart J"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B78","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2165\/11630960-000000000-00000","article-title":"Pharmacokinetic, pharmacodynamic and pharmacogenetic profile of the oral antiplatelet agent ticagrelor","volume":"51","year":"2012","journal-title":"Clin Pharmacokinet"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B79","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/jth.12445","article-title":"Clinical implications of drug-drug interactions with P2Y12 receptor inhibitors","volume":"12","year":"2014","journal-title":"J Thromb Haemost"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B80","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11739-013-1000-4","article-title":"Proton pump inhibitors and clopidogrel: an association to avoid?","volume":"9","year":"2014","journal-title":"Intern Emerg Med"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B81","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1742-7843.2012.00932.x","article-title":"Pharmacokinetic interaction between prasugrel and ritonavir in healthy volunteers","volume":"112","year":"2013","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B82","first-page":"630","article-title":"Morphine decreases clopidogrel concentrations and effects: a randomized, double-blind, placebo-controlled trial","volume":"63","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B83","first-page":"245","article-title":"Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial","volume":"37","year":"2015","journal-title":"European Heart Journal"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B84","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ijcard.2016.04.077","article-title":"Impact of morphine on antiplatelet effects of oral P2Y12 receptor inhibitors","volume":"215","year":"2016","journal-title":"Int J Cardiol"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B85","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/eurheartj\/ehv547","article-title":"Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial","volume":"37","year":"2016","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B86","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.tig.2003.09.008","article-title":"Pharmacogenetics: potential for individualized drug therapy through genetics","volume":"19","year":"2003","journal-title":"Trends Genet"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B87","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1111\/jth.12318","article-title":"Pharmacogenomics in cardiovascular disease: focus on aspirin and ADP receptor antagonists","volume":"11","year":"2013","journal-title":"J Thromb Haemost"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B88","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1161\/CIRCINTERVENTIONS.111.963025","article-title":"CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients","volume":"4","year":"2011","journal-title":"Circ Cardiovasc Interv"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B89","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.amjcard.2008.11.048","article-title":"Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis","volume":"103","year":"2009","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B90","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(08)61845-0","article-title":"Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study","volume":"373","year":"2009","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B91","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa0809171","article-title":"Cytochrome p-450 polymorphisms and response to clopidogrel","volume":"360","year":"2009","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B92","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/jama.2009.1232","article-title":"Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy","volume":"302","year":"2009","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B93","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1538-7836.2012.04639.x","article-title":"Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study","volume":"10","year":"2012","journal-title":"J Thromb Haemost"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B94","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1093\/eurheartj\/ehs059","article-title":"The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study","volume":"33","year":"2012","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B95","doi-asserted-by":"crossref","first-page":"e102701","DOI":"10.1371\/journal.pone.0102701","article-title":"Interplay between Genetic and Clinical Variables Affecting Platelet Reactivity and Cardiac Adverse Events in Patients Undergoing Percutaneous Coronary Intervention","volume":"9","year":"2014","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B96","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1001\/jama.2010.1543","article-title":"Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis","volume":"304","year":"2010","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B97","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nrcardio.2015.64","article-title":"Genotype-based clinical trials in cardiovascular disease","volume":"12","year":"2015","journal-title":"Nat Rev Cardiol"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B98","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJMoa0808227","article-title":"Genetic determinants of response to clopidogrel and cardiovascular events","volume":"360","year":"2009","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B99","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1093\/eurheartj\/ehq321","article-title":"CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study","volume":"31","year":"2010","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B100","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1161\/CIRCINTERVENTIONS.111.962555","article-title":"Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin","volume":"4","year":"2011","journal-title":"Circ Cardiovasc Interv"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B101","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1161\/CIRCULATIONAHA.109.885194","article-title":"Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement","volume":"121","year":"2010","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B102","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1111\/j.1538-7836.2009.03500.x","article-title":"The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syndrome","volume":"7","year":"2009","journal-title":"J Thromb Haemost"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B103","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/S0140-6736(10)61273-1","article-title":"Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis","volume":"376","year":"2010","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B104","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1161\/CIRCINTERVENTIONS.111.965400","article-title":"No association of ABCB1 C3435T genotype with clopidogrel response or risk of stent thrombosis in patients undergoing coronary stenting","volume":"5","year":"2012","journal-title":"Circ Cardiovasc Interv"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B105","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1111\/j.1538-7836.2011.04457.x","article-title":"Relationship between paraoxonase Q192R gene polymorphism and on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention","volume":"9","year":"2011","journal-title":"J Thromb Haemost"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B106","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/S0140-6736(10)61274-3","article-title":"Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial","volume":"376","year":"2010","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B107","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1161\/01.CIR.0000085073.69189.88","article-title":"Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects","volume":"108","year":"2003","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B108","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1161\/CIRCULATIONAHA.109.851949","article-title":"Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes","volume":"119","year":"2009","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B109","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1161\/CIRCGENETICS.110.958561","article-title":"First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET\/OFFSET and RESPOND genotype studies","volume":"3","year":"2010","journal-title":"Circ Cardiovasc Genet"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B110","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.ahj.2010.12.011","article-title":"The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy","volume":"161","year":"2011","journal-title":"Am Heart J"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B111","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jacc.2014.03.051","article-title":"Variability of individual platelet reactivity over time in patients treated with clopidogrel: insights from the ELEVATE-TIMI 56 trial","volume":"64","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B112","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S0140-6736(12)60161-5","article-title":"Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial","volume":"379","year":"2012","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B113","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ahj.2010.09.029","article-title":"Randomized comparison of platelet function monitoring to adjust antiplatelet therapy versus standard of care: rationale and design of the assessment with a double randomization of (1) a fixed dose versus a monitoring-guided dose of aspirin and clopidogrel after DES implantation, and (2) treatment interruption versus continuation, 1 year after stenting (ARCTIC) study","volume":"161","year":"2011","journal-title":"Am Heart J"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B114","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/jth.12059","article-title":"Genetic testing in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cost-effectiveness analysis","volume":"11","year":"2013","journal-title":"J Thromb Haemost"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B115","doi-asserted-by":"crossref","first-page":"5379","DOI":"10.2174\/138161212803251862","article-title":"Platelet function testing in atherothrombotic disease","volume":"18","year":"2012","journal-title":"Curr Pharm Des"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B116","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2217\/bmm.10.122","article-title":"Functional testing methods for the antiplatelet effects of aspirin","volume":"5","year":"2011","journal-title":"Biomark Med"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B117","first-page":"259","article-title":"Personalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfalls","volume":"11","year":"2015","journal-title":"Postepy Kardiol Interwencyjnej"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B118","first-page":"133","article-title":"Platelet function tests: a comparative review","volume":"11","year":"2015","journal-title":"Vasc Health Risk Manag"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B119","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1016\/j.jacc.2005.07.041","article-title":"Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study","volume":"46","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B120","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1160\/TH07-04-0296","article-title":"ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome","volume":"98","year":"2007","journal-title":"Thromb Haemost"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B121","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/j.1399-6576.2008.01845.x","article-title":"Platelet concentrates transfusion in cardiac surgery and platelet function assessment by multiple electrode aggregometry","volume":"53","year":"2009","journal-title":"Acta Anaesthesiol Scand"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B122","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.athoracsur.2010.09.022","article-title":"Multiple electrode whole-blood aggregometry and bleeding in cardiac surgery patients receiving thienopyridines","volume":"91","year":"2011","journal-title":"Ann Thorac Surg"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B123","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1093\/eurheartj\/ehn046","article-title":"Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation","volume":"29","year":"2008","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B124","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1161\/CIRCULATIONAHA.108.812636","article-title":"Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up","volume":"119","year":"2009","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B125","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1160\/TH07-05-0324","article-title":"The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis","volume":"98","year":"2007","journal-title":"Thromb Haemost"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B126","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1111\/j.1538-7836.2007.02609.x","article-title":"Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events","volume":"5","year":"2007","journal-title":"J Thromb Haemost"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B127","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.thromres.2005.10.011","article-title":"Platelet activation predicts recurrent ischemic events after percutaneous coronary angioplasty: a 6 months prospective study","volume":"118","year":"2006","journal-title":"Thromb Res"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B128","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1111\/j.1538-7836.2006.02239.x","article-title":"Platelet function in patients with acute coronary syndrome (ACS) predicts recurrent ACS","volume":"4","year":"2006","journal-title":"J Thromb Haemost"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B129","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ejim.2011.02.021","article-title":"Residual platelet reactivity after aspirin and clopidogrel treatment predicts 2-year major cardiovascular events in patients undergoing percutaneous coronary intervention","volume":"22","year":"2011","journal-title":"Eur J Intern Med"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B130","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1111\/j.1538-7836.2008.03112.x","article-title":"Prognostic value of serial platelet reactivity measurements on long-term clinical outcome in patients with ST-elevation myocardial infarction undergoing primary PCI","volume":"6","year":"2008","journal-title":"J Thromb Haemost"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B131","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1067\/mlc.2001.117406","article-title":"Platelet function analyzer (PFA-100): a tool to quantify congenital or acquired platelet dysfunction","volume":"138","year":"2001","journal-title":"J Lab Clin Med"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B132","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1080\/09537100801989857","article-title":"Effects of aspirin and clopidogrel in healthy men measured by platelet aggregation and PFA-100","volume":"19","year":"2008","journal-title":"Platelets"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B133","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1160\/TH09-08-0527","article-title":"A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease","volume":"103","year":"2010","journal-title":"Thromb Haemost"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B134","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1537-2995.2007.01070.x","article-title":"Monitoring survival and function of transfused platelets in Bernard-Soulier syndrome by flow cytometry and a cone and plate(let) analyzer (Impact-R)","volume":"47","year":"2007","journal-title":"Transfusion"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B135","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1055\/s-0038-1649720","article-title":"Inhibition of integrin-mediated platelet aggregation, fibrinogen-binding, and interactions with extracellular matrix by nonpeptidic mimetics of Arg-Gly-Asp","volume":"70","year":"1993","journal-title":"Thromb Haemost"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B136","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.lab.2004.01.011","article-title":"A novel modification of the Thrombelastograph assay, isolating platelet function, correlates with optical platelet aggregation","volume":"143","year":"2004","journal-title":"J Lab Clin Med"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B137","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1080\/09537100802657735","article-title":"Evaluation of the Platelet Mapping Assay on rotational thromboelastometry ROTEM","volume":"20","year":"2009","journal-title":"Platelets"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B138","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.amjcard.2008.08.048","article-title":"Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis","volume":"103","year":"2009","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B139","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.jacc.2007.12.044","article-title":"Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study","volume":"51","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B140","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/j.ijcard.2012.05.040","article-title":"Personalized antiplatelet treatment after percutaneous coronary intervention: the MADONNA study","volume":"167","year":"2013","journal-title":"Int J Cardiol"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B141","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1161\/CIRCULATIONAHA.108.833236","article-title":"Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and\/or Resistance to Clopidogrel study","volume":"119","year":"2009","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B142","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.jcin.2008.08.018","article-title":"Glycoprotein IIb\/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study","volume":"1","year":"2008","journal-title":"JACC Cardiovasc Interv"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B143","doi-asserted-by":"crossref","first-page":"e005781","DOI":"10.1136\/bmjopen-2014-005781","article-title":"Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry","volume":"4","year":"2014","journal-title":"BMJ Open"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B144","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1001\/jama.2011.290","article-title":"Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial","volume":"305","year":"2011","journal-title":"Jama"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B145","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1016\/j.jacc.2012.02.026","article-title":"A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study","volume":"59","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B146","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1056\/NEJMoa1209979","article-title":"Bedside Monitoring to Adjust Antiplatelet Therapy for Coronary Stenting","volume":"367","year":"2012","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B147","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1161\/CIRCULATIONAHA.113.007524","article-title":"High on-treatment platelet reactivity as a risk factor for secondary prevention after coronary stent revascularization: A landmark analysis of the ARCTIC study","volume":"129","year":"2014","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B148","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/S0140-6736(16)31323-X","article-title":"Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial","volume":"388","year":"2016","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B149","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1160\/TH14-03-0238","article-title":"How to improve the concept of individualised antiplatelet therapy with P2Y12 receptor inhibitors\u2013is an algorithm the answer?","volume":"113","year":"2015","journal-title":"Thromb Haemost"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B150","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1160\/TH13-03-0250","article-title":"Why have studies of tailored anti-platelet therapy failed so far?","volume":"110","year":"2013","journal-title":"Thromb Haemost"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B151","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S0140-6736(13)61170-8","article-title":"Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study","volume":"382","year":"2013","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B152","first-page":"2140","article-title":"Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: Systematic review and meta-analysis","volume":"167","year":"2012","journal-title":"Int J Cardiol"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B153","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1056\/NEJMoa1209979","article-title":"Bedside monitoring to adjust antiplatelet therapy for coronary stenting","volume":"367","year":"2012","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B154","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1001\/jama.2012.17312","article-title":"Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy","volume":"308","year":"2012","journal-title":"Jama"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B155","doi-asserted-by":"crossref","first-page":"528","DOI":"10.3109\/09537104.2012.738838","article-title":"Increased platelet aggregation and turnover in the acute phase of ST-elevation myocardial infarction","volume":"24","year":"2013","journal-title":"Platelets"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B156","first-page":"230","article-title":"Resistance to antiplatelet drugs: molecular mechanisms and laboratory detection","volume":"5 Suppl 1","year":"2007","journal-title":"J Thromb Haemost"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B157","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1160\/TH12-10-0718","article-title":"Hirudin anticoagulation allows more rapid determination of P2Y(1)(2) inhibition by the VerifyNow P2Y12 assay","volume":"109","year":"2013","journal-title":"Thromb Haemost"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B158","author":"S. S. Clopidogrel Genotyping for Antiplatelet Guidance in MI Stenting: Maybe Reduced Ischemic Risk","year":"2013"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B159","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.jacc.2013.12.023","article-title":"Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel","volume":"63","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B160","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1136\/qhc.12.1.18","article-title":"Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project","volume":"12","year":"2003","journal-title":"Qual Saf Health Care"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B161","doi-asserted-by":"crossref","first-page":"h1302","DOI":"10.1136\/bmj.h1302","article-title":"Precision medicine to improve use of bleeding avoidance strategies and reduce bleeding in patients undergoing percutaneous coronary intervention: prospective cohort study before and after implementation of personalized bleeding risks","volume":"350","year":"2015","journal-title":"BMJ"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B162","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1093\/eurheartj\/ehv226","article-title":"Cardiovascular precision medicine: hope or hype?","volume":"36","year":"2015","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B163","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1056\/NEJMp1114866","article-title":"Preparing for precision medicine","volume":"366","year":"2012","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B164","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1161\/CIR.0b013e31823a5596","article-title":"2011 ACCF\/AHA\/SCAI Guideline for Percutaneous Coronary Intervention: executive summary: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions","volume":"124","year":"2011","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B165","first-page":"2221","article-title":"Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease","volume":"306","year":"2011","journal-title":"Jama"},{"key":"key\n\t\t\t\t20171011230541_pvw044-B166","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/s00228-015-1917-9","article-title":"Genetic and platelet function testing of antiplatelet therapy for percutaneous coronary intervention: the ARCTIC-GENE study","volume":"71","year":"2015","journal-title":"Eur J Clin Pharmacol"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ehjcvp\/article-pdf\/3\/4\/221\/19785219\/pvw044.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T07:15:50Z","timestamp":1692688550000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/ehjcvp\/article\/3\/4\/221\/2999318\/Advocating-cardiovascular-precision-medicine-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,15]]},"references-count":166,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2017,2,15]]},"published-print":{"date-parts":[[2017,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvw044","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,10]]},"published":{"date-parts":[[2017,2,15]]}}}